Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting

Author:

Sadouki Zahra12,McHugh Timothy D.2,Aarnoutse Rob3,Ortiz Canseco Julio2,Darlow Christopher4,Hope William4,van Ingen Jakko5ORCID,Longshaw Christopher6,Manissero Davide7,Mead Andrew8,Pelligand Ludovic8,Phee Lynette9,Readman John10,Ruth Mike M.3ORCID,Standing Joseph F.10ORCID,Stone Neil11,Wey Emmanuel Q.12,Kloprogge Frank1ORCID

Affiliation:

1. Institute for Global Health, University College London, London, UK

2. Centre of Clinical Microbiology, University College London, London, UK

3. Department of Internal Medicine, Radboud Center of Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands

4. Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, UK

5. Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands

6. Medical Affairs, Shionogi Europe, London, UK

7. Medical Affairs for Infection and Immune Diagnostics, QIAGEN, London, UK

8. Department of Comparative Biological Sciences, The Royal Veterinary College, London, UK

9. Antimicrobial Research Group, Barts and The London School of Medicine and Dentistry, Queen Mary University London, London, UK

10. Infection, Immunity, Inflammation Section, University College London Great Ormond Street Institute of Child Health, London, UK

11. Department of Microbiology, University College London Hospitals, London, UK

12. Royal Free London NHS Trust, London, UK

Abstract

Abstract Objectives This systematic review focuses on the use of the in vitro hollow fibre infection model (HFIM) for microbial culture. We summarize the direction of the field to date and propose best-practice principles for reporting of the applications. Methods Searches in six databases (MEDLINE®, EMBASE®, PubMed®, BIOSIS®, SCOPUS® and Cochrane®) up to January 2020 identified 129 studies meeting our inclusion criteria. Two reviewers independently assessed and extracted data from each publication. The quality of reporting of microbiological and technical parameters was analysed. Results Forty-seven out of 129 (36.4%) studies did not report the minimum pharmacokinetic parameters required in order to replicate the pharmacokinetic profile of HFIM experiments. Fifty-three out of 129 (41.1%) publications did not report the medium used in the HFIM. The overwhelming majority of publications did not perform any technical repeats [107/129 (82.9%)] or biological repeats [97/129 (75.2%)]. Conclusions This review demonstrates that most publications provide insufficient data to allow for results to be evaluated, thus impairing the reproducibility of HFIM experiments. Therefore, there is a clear need for the development of laboratory standardization and improved reporting of HFIM experiments.

Funder

Shionogi B.V. and by the University College London Institute for Global Health (IGH) and Centre for Clinical Microbiology

United Kingdom Medical Research Council (MRC) Fellowship

Wellcome Trust and the Royal Society

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3